Search results for "pyoderma gangrenosum"

showing 10 items of 12 documents

ISOLATED PYODERMA GANGRENOSUM AND ADALIMUMAB:CASE REPORT IN PAEDIATRIC AGE

2018

Introduction: Pyoderma Gangrenosum (PG) is a sterile neutrophilic disorder, rarely described in children and adolescents, and frequently it is known as secondary to other chronic inflammatory diseases. However, epidemiological, clinical and therapeutic data on paediatric PG are numerically limited and no randomized controlled trials have been published. Associated diseases in paediatric cases are inflammatory bowel diseases, vasculitis, immune deficiencies, PAPA Syndrome. The treatment with systemic steroids and cyclosporine is well documented in the literature as the first-line treatment. In nonresponders, other treatment lines are indicated, as: corticosteroids and mycophenolate mofetil, …

Settore MED/38 - Pediatria Generale E SpecialisticaPYODERMA GANGRENOSUM ADALIMUMAB NEUTROPHILIC DISORDER
researchProduct

Multifocal Pyoderma Gangrenosum Resistant to Infliximab in Active Ulcerative Colitis: Donʼt Forget the Role of Cyclosporin

2012

medicine.medical_specialtybusiness.industryGastroenterologymedicineImmunology and Allergymedicine.diseasebusinessUlcerative colitisDermatologyPyoderma gangrenosumInfliximabmedicine.drugInflammatory Bowel Diseases
researchProduct

Post Surgical Pyoderma Gangrenosum in flap surgery: diagnostic clues and treatment recommendations

2016

Background: Post Surgical Pyoderma Gangrenosum (PSPG) is a neutrophilic dermatosis causing aseptic necrotic ulcerations within surgical sites. It is often misdiagnosed as infection or ischemia and worsened by the inappropriate treatment. Therefore diagnostic clues must be identified and awareness for PSPG raised.Methods: We present two cases of PSPG after flap surgery and a review of the literature.Results: Seventeen cases of PSPG after flap surgery were found. Fever, pain and redness are the most common initial symptoms. In 63%, lesions were on the flap and the adjacent skin. In 63%, the donor site is also involved. Time to diagnosis was nine days to four years. Frequent debridement (89%) …

Malemedicine.medical_specialtyPost surgicalNecrosisTuberculosisPrognosiSettore MED/19 - Chirurgia PlasticaIschemia030230 surgeryAdrenal Cortex HormoneRisk AssessmentSeverity of Illness IndexSurgical Flaps030207 dermatology & venereal diseases03 medical and health sciencesPostoperative Complications0302 clinical medicineAdrenal Cortex HormonesPost Surgical Pyoderma GangrenosummedicineHumansflap surgeryskin and connective tissue diseasesAgedWound Healingbusiness.industryGeneral MedicineMiddle AgedPrognosismedicine.diseaseDermatologyPyoderma GangrenosumSurgerySurgical FlapDebridementFemaleSurgeryPostoperative ComplicationAseptic processingmedicine.symptombusinessBreast reconstructionComplicationPyoderma gangrenosumHumanActa Chirurgica Belgica
researchProduct

P114 A screening tool for the early diagnosis of extraintestinal manifestations in inflammatory bowel disease: the EMAIL questionnaire

2020

Abstract Background Data on prevalence of extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD) range from 6% up to 47%. Recently, several red flags and questionnaires have been proposed for early diagnosis of articular manifestations. Our aim was to analyse the prevalence of EIMs in a single-centre prospective cohort, using a comprehensive questionnaire developed by our group to detect all EIMs (EMAIL questionnaire). Methods Patients with IBD attending our Clinic from November 2017 to January 2019 were interviewed using a two-part questionnaire, the first part for clinical-demographic data and the second part for EIMs. Patients positive to screening were referred for mu…

Erythema nodosumAnkylosing spondylitismedicine.medical_specialtyCrohn's diseasebusiness.industryGastroenterologySacroiliitisGeneral Medicinemedicine.diseaseUlcerative colitisInflammatory bowel diseaseInternal medicinePsoriasismedicinebusinessPyoderma gangrenosumJournal of Crohn's and Colitis
researchProduct

SISTEMIC MANIFESTATIONS IN CROHN DISEASE: OUR EXPERIENCE

2009

Arthritis and Crohm's disease has a close link and are frequently associated with aspecific and specific dermatitis. The arthritis is counted as the worst side effect of Crohn's disease. The greatest part of chronic inflammatory bowel disease induce with dermatologic disease, tha are sometimes the first clinical manifestation. In this article the authors desrcibe their clinical observation about orthopaedic, dermatologic and gastroenteric manifestations.

CROHN DISEASE ARTHRITIS DISEASE PYODERMA GANGRENOSUM
researchProduct

Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

2019

Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …

medicine.medical_specialtyDiseaseDiagnostic toolsSeverity of Illness Index030226 pharmacology & pharmacySystemic therapyBiological Factors03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesmedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsIntensive care medicineClinical treatmentbusiness.industryGeneral MedicineGold standard (test)medicine.diseasePyoderma GangrenosumBiologic AgentsNeutrophilic dermatosis030220 oncology & carcinogenesisDisease ProgressionDermatologic AgentsbusinessImmunosuppressive AgentsPyoderma gangrenosumExpert Review of Clinical Pharmacology
researchProduct

PAPA and FMF in two siblings: possible amplification of clinical presentation? A case report

2019

Abstract Background Familial Mediterranean Fever is a monogenic autoinflammatory disease, typically characterized by recurrent attacks of fever, serositis, aphthous of oral mucosa, erythema. “Pyogenic arthritis, pyoderma gangrenosum and acne syndrome” is a rare autoinflammatory disease with variable expression and typically involving joints and skin. Both the diseases are linked by the overproduction of IL-1. Case presentation We report on the case of two siblings affected by recurrent attacks of fever, oral aphthous stomatitis, abdominal pain, arthritis, undefined dermatitis at the hands, associated with increased AST, ALT, C-reactive protein, erythrocyte sedimentation rate, serum amyloid …

MaleAbdominal painmedicine.medical_specialtyAdolescentCanakinumabFamilial Mediterranean feverArthritisCase ReportFamilial Mediterranean fever03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicine030225 pediatricsAcne VulgarismedicineHumans030212 general & internal medicineChildPyogenic arthritis pyoderma gangrenosum and acne syndromeArthritis InfectiousFamilial Mediterranean fever Pyogenic arthritis pyoderma gangrenosum and acne syndrome Colchicine Canakinumabbusiness.industrylcsh:RJ1-570lcsh:PediatricsPAPA syndromemedicine.diseaseMEFVDermatologyPyoderma GangrenosumCanakinumabmedicine.symptombusinessColchicineSerositisPyoderma gangrenosummedicine.drugItalian Journal of Pediatrics
researchProduct

Ulcerative pyoderma gangrenosum associated with cocaine use

2020

Cocaine-Related Disordersmedicine.medical_specialtyCocainebusiness.industrymedicineCocaine useHumansColitis Ulcerativemedicine.diseasebusinessDermatologyPyoderma GangrenosumPyoderma gangrenosumMedicina Clínica (English Edition)
researchProduct

797 Infliximab in the Treatment of Pediatric Ibd: A Single Centre Experience

2010

Background and aims: The biological treatment of IBD acts on different stages of immunophysiopathological processes of the disease. We describe evolution and clinical response to Infliximab in paediatric patients affected by IBD diagnosed and followed at our centre. Methods: In the last triennial period at our Department of Paediatrics in Palermo 53 infusions of Infliximab were administrated to our patients affected by severe forms of IBD. All patients but one were affected by several forms of CD. Only one child was affected by U.C. associated to pyoderma gangrenosum. The total number of infusions were administrated according the ACCENT 1 study at a dose of 5 mg/Kg. All the infusions were p…

Drugmedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectDiseasemedicine.diseaseInfliximabDiscontinuationSingle centreTolerabilityInternal medicinePediatrics Perinatology and Child HealthmedicinebusinessPyoderma gangrenosummedia_commonPaediatric patientsmedicine.drugPediatric Research
researchProduct

PA1 INFLIXIMAB AND TOPICAL TACROLIMUS ADMINISTRATION EFFECTIVE IN THE TREATMENT OF PYODERMA GANGRENOSUM

2009

medicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicineTopical tacrolimusmedicine.diseasebusinessAdministration (government)DermatologyPyoderma gangrenosumInfliximabmedicine.drugDigestive and Liver Disease
researchProduct